Centocor Contract

Daniel Penn Associates Contracted by Centocor to Develop Facility Maintenance Processes for New Early Stage Facility

Hartford, CT - August 2002

Daniel Penn Associates (DPA) has been awarded of a contract with Centocor, a wholly owned subsidiary of Johnson & Johnson.

DPA will develop facility and production Preventive Maintenance processes and procedures, coordinate utility system SOP training, and develop the spare parts inventory for the first phase of Centocor's new Early Stage Facility in Spring House, PA.

Preventive maintenance in the pharmaceutical industry is more than just a smart business practice -- a comprehensive PM program is a requirement before equipment can be validated for use by the FDA. Proper Preventive Maintenance procedures are recognized as necessary to ensure the consistent quality and effectiveness of pharmaceutical products.

Centocor, Inc. is a leading, fully integrated biopharmaceutical company specializing in the development and commercialization of therapeutic products to meet critical human health care needs. A world leader in monoclonal antibody technology and manufacturing, Centocor's innovative products include REMICADE (infliximab) used in combination with methotrexate for reducing the signs and symptoms and inhibiting the progression of joint damage in patients with moderately to severely active rheumatoid arthritis who have not responded to methotrexate alone and for the short term treatment of Crohn's disease; REOPRO (abciximab) for use in percutaneous coronary intervention; and RETAVASE (reteplase), a clot buster that is administered during heart attack.

###

DPA . . .   Articles  |  Case Studies  |  News Releases